Prime Vitality Inc dba Prime Peptides: FDA Warning Letter 695156-12102024

Updated August 21, 2026

Prime Vitality Inc dba Prime Peptides received FDA warning letter 695156-12102024, dated December 10, 2024, one of four same-day letters to research-peptide vendors. FDA determined that the firm's semaglutide-, tirzepatide-, and retatrutide-class products were unapproved new drugs, with research-use-only labeling outweighed, in the agency's view, by the firm's own published evidence.

The letter

Warning letter 695156-12102024 is addressed to Prime Vitality Inc, doing business as Prime Peptides, and is published in full on fda.gov (linked under Sources). Its subject matter is the firm's GLP-1-class catalog — products in the semaglutide, tirzepatide, and retatrutide class — which FDA classified as unapproved new drugs for purposes of the Federal Food, Drug, and Cosmetic Act. The letter set a 15-working-day deadline for the firm's written reply. As with any warning letter, the document is an agency compliance action and a public record of documented findings; it is not a judicial ruling, and it makes no statement about the analytical character of any shipped material.

The finding as FDA states it

The central finding concerns the gap between labeling and intended use. Per the agency's record, the products carried research-use-only language, yet evidence FDA gathered from the firm's website and social presence established, in FDA's assessment, that the products were intended for human use as drugs. Intended use, on this reading, is not fixed by a label; the agency weighs the whole of what a firm publishes. This index reports that position as FDA's stated determination — the characterization is the agency's throughout.

The December 10, 2024 batch

The Prime Peptides letter did not issue alone. Four research-peptide vendors received letters bearing the same date, all involving the GLP-1 class and all resting on the same labeling-versus-evidence finding:

The position restated in later enforcement

The finding at the center of letter 695156-12102024 did not remain confined to this batch. In its seven letters dated March 31, 2026 (posted April 7, 2026), FDA repeated the doctrine in near-identical terms — stating that material drawn from a seller's own website can establish the products as intended drugs for human use, research-use disclaimers notwithstanding — while adding new categories of cited evidence, including administration supplies offered in the same shopping cart and coded drug names. The December 2024 batch thus reads, in sequence, as an early statement of a position the agency has since maintained; the full chronology appears on the enforcement timeline and across the vendor index.

Sources

1. FDA Warning Letter 695156-12102024, Prime Vitality Inc dba Prime Peptides — the primary record.
2. FDA Warning Letter 695607-12102024, Summit Research Peptides — same-day batch letter.
3. FDA Warning Letter 694608-12102024, Xcel Research LLC — same-day batch letter.
4. FDA Warning Letters index (searchable) — for the SwissChems batch letter.
5. FDA Roundup, December 17, 2024 — agency summary of the batch.

Further reading

1. PureRawz: FDA warning letter record (September 8, 2025) — the other vendor cited in an FDA compounding briefing document and later sent a letter. In both cases the letter concerned different products than the evaluation had surveyed.
2. Full vendor index — every entity record
3. Artemis Labs: what the intended-use doctrine means when auditing a successor vendor

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.